Mealey's Antitrust/Unfair Competition - $190M Neurontin Antitrust Pact Gets Preliminary Approval From Federal MDL Judge

NEWARK, N.J. - A New Jersey federal judge on May 2 preliminarily approved a $190 million antitrust class settlement of allegations that Pfizer Inc. and a predecessor kept generic Neurontin off the market, causing commercial direct buyers to pay more for the brand-name drug (In Re: Neurontin Antitrust Litigation, MDL Docket No. 1479, No. 02-1390, Louisiana Wholesale Drug Company, Inc., et al., Nos. 02-1830 and 02-2731, D. N.J.).

Access this news story on®